{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T12:22:00Z","timestamp":1722946920794},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T00:00:00Z","timestamp":1459123200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0151703","type":"journal-article","created":{"date-parts":[[2016,3,28]],"date-time":"2016-03-28T17:40:33Z","timestamp":1459186833000},"page":"e0151703","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: Results from the GUARD-C Cohort"],"prefix":"10.1371","volume":"11","author":[{"given":"Graham R.","family":"Foster","sequence":"first","affiliation":[]},{"given":"Carmine","family":"Coppola","sequence":"additional","affiliation":[]},{"given":"Moutaz","family":"Derbala","sequence":"additional","affiliation":[]},{"given":"Peter","family":"Ferenci","sequence":"additional","affiliation":[]},{"given":"Alessandra","family":"Orlandini","sequence":"additional","affiliation":[]},{"given":"K. Rajender","family":"Reddy","sequence":"additional","affiliation":[]},{"given":"Ludovico","family":"Tallarico","sequence":"additional","affiliation":[]},{"given":"Mitchell L.","family":"Shiffman","sequence":"additional","affiliation":[]},{"given":"Silke","family":"Ahlers","sequence":"additional","affiliation":[]},{"given":"Georgios","family":"Bakalos","sequence":"additional","affiliation":[]},{"given":"Tarek","family":"Hassanein","sequence":"additional","affiliation":[]},{"name":"GUARD-C Study Group","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2016,3,28]]},"reference":[{"unstructured":"American Association for the Study of Liver Diseases and Infectious Diseases Society of America. Recommendations for testing, managing, and treating hepatitis C. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.hcvguidelines.org\" xlink:type=\"simple\">http:\/\/www.hcvguidelines.org<\/ext-link>. Accessed 24 Aug 2014.","key":"ref1"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMe1401508","article-title":"Therapy for hepatitis C\u2014the costs of success","volume":"370","author":"JH Hoofnagle","year":"2014","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/ajg.2014.66","article-title":"The rapid evolution of treatment strategies for hepatitis C","volume":"109","author":"AJ Muir","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0140-6736(14)60087-8","article-title":"Only just the beginning of the end of hepatitis C","volume":"383","year":"2014","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1056\/NEJMp1400160","article-title":"Treating hepatitis C in lower-income countries","volume":"370","author":"CR Jayasekera","year":"2014","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update","volume":"49","author":"MG Ghany","year":"2009","journal-title":"Hepatology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1053\/gast.2002.35950","article-title":"Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C","volume":"123","author":"JG McHutchison","year":"2002","journal-title":"Gastroenterology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.cgh.2006.10.008","article-title":"Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a\/ribavirin treatment","volume":"5","author":"KR Reddy","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1002\/hep.24180","article-title":"Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1","volume":"53","author":"W Sievert","year":"2011","journal-title":"Hepatology"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/pds.1082","article-title":"Guidelines for good pharmacoepidemiology practices (GPP)","volume":"14","author":"M Epstein","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1111\/liv.12439","article-title":"A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)\/ribavirin","volume":"34","author":"P Ferenci","year":"2014","journal-title":"Liver Int"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1007\/s10620-011-1765-0","article-title":"Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomized controlled trials","volume":"56","author":"AK Singal","year":"2011","journal-title":"Dig Dis Sci"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"D Ge","year":"2009","journal-title":"Nature"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"MP Manns","year":"2001","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection","volume":"347","author":"MW Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"346","DOI":"10.7326\/0003-4819-140-5-200403020-00010","article-title":"Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose","volume":"140","author":"SJ Hadziyannis","year":"2004","journal-title":"Ann Intern Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/jvh.12179","article-title":"Impact of age on viral kinetics of peginterferon alfa-2a\/ribavirin in chronic hepatitis C: final analysis from the PROPHESYS cohort","volume":"21","author":"A Aronsohn","year":"2014","journal-title":"J Viral Hepat"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/j.1365-2893.2009.01186.x","article-title":"Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C","volume":"16","author":"F Negro","year":"2009","journal-title":"J Viral Hepat"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/j.gastro.2010.08.051","article-title":"Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads","volume":"139","author":"KR Reddy","year":"2010","journal-title":"Gastroenterology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1056\/NEJMoa0808010","article-title":"Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection","volume":"361","author":"JG McHutchison","year":"2009","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1053\/j.gastro.2010.07.059","article-title":"Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate","volume":"139","author":"MS Sulkowski","year":"2010","journal-title":"Gastroenterology"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2007.11.020","article-title":"Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C","volume":"6","author":"KL Lindsay","year":"2008","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0151703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T19:55:57Z","timestamp":1540324557000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0151703"}},"subtitle":[],"editor":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2016,3,28]]},"references-count":22,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0151703","relation":{},"ISSN":["1932-6203"],"issn-type":[{"type":"electronic","value":"1932-6203"}],"subject":[],"published":{"date-parts":[[2016,3,28]]}}}